v3.26.3
Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Assets:          
Derivative asset $ 30,973   $ 30,973   $ 15,632
Total assets 539,643   $ 539,643   $ 726,988
Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag     Derivative assets   Derivative assets
Liabilities:          
Derivative liabilities 279   $ 279   $ 0
Total liabilities 39,146   39,146   3,221
RemainCo          
Assets:          
Equity Method Investments, Fair Value Disclosure 13,700   13,700    
Common Stock          
Assets:          
Pelthos Common Shares 31,515   31,515   46,500
Metabasis          
Liabilities:          
(Decrease) increase of mark-to-market adjustment of CVR liability 1,100 $ (500) 600 $ 1,400  
Short-Term Investments          
Assets:          
Investments, fair value 391,437   391,437   558,594
Preferred Stock          
Assets:          
Investments, fair value 72,018   72,018   106,262
Contingent liabilities          
Liabilities:          
Contingent liabilities 38,867   38,867   3,221
Contingent liabilities | CyDex          
Liabilities:          
Contingent liabilities 422   422   395
Contingent liabilities | Metabasis          
Liabilities:          
Contingent liabilities 3,308   3,308   2,826
Contingent liabilities | HilleVax          
Liabilities:          
Contingent liabilities 14,600   14,600   0
Contingent liabilities | LAVA          
Liabilities:          
Contingent liabilities 6,738   6,738   0
Contingent liabilities | BioInvent          
Liabilities:          
Contingent liabilities 3,300   3,300   0
Contingent liabilities | Pulmokine          
Liabilities:          
Contingent liabilities 4,700   4,700   0
Contingent liabilities | Kinnate          
Liabilities:          
Contingent liabilities 3,700   3,700   0
Contingent liabilities | Kinnate CVR - Exarafenib          
Liabilities:          
Contingent liabilities 2,000   2,000   0
Contingent liabilities | Other          
Liabilities:          
Contingent liabilities 99   99   0
Level 1          
Assets:          
Derivative asset 0   0   0
Total assets 252,434   252,434   336,744
Liabilities:          
Derivative liabilities 0   0   0
Total liabilities 0   0   0
Level 1 | RemainCo          
Assets:          
Equity Method Investments, Fair Value Disclosure 0   0    
Level 1 | Common Stock          
Assets:          
Pelthos Common Shares 31,515   31,515   46,500
Level 1 | Short-Term Investments          
Assets:          
Investments, fair value 148,901   148,901   183,982
Level 1 | Preferred Stock          
Assets:          
Investments, fair value 72,018   72,018   106,262
Level 1 | Contingent liabilities          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | CyDex          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | Metabasis          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | HilleVax          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | LAVA          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | BioInvent          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | Pulmokine          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | Kinnate          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | Kinnate CVR - Exarafenib          
Liabilities:          
Contingent liabilities 0   0   0
Level 1 | Contingent liabilities | Other          
Liabilities:          
Contingent liabilities 0   0   0
Level 2          
Assets:          
Derivative asset 22,685   22,685   10,643
Total assets 265,221   265,221   385,255
Liabilities:          
Derivative liabilities 279   279   0
Total liabilities 3,587   3,587   2,826
Level 2 | RemainCo          
Assets:          
Equity Method Investments, Fair Value Disclosure 0   0    
Level 2 | Common Stock          
Assets:          
Pelthos Common Shares 0   0   0
Level 2 | Short-Term Investments          
Assets:          
Investments, fair value 242,536   242,536   374,612
Level 2 | Preferred Stock          
Assets:          
Investments, fair value 0   0   0
Level 2 | Contingent liabilities          
Liabilities:          
Contingent liabilities 3,308   3,308   2,826
Level 2 | Contingent liabilities | CyDex          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | Metabasis          
Liabilities:          
Contingent liabilities 3,308   3,308   2,826
Level 2 | Contingent liabilities | HilleVax          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | LAVA          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | BioInvent          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | Pulmokine          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | Kinnate          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | Kinnate CVR - Exarafenib          
Liabilities:          
Contingent liabilities 0   0   0
Level 2 | Contingent liabilities | Other          
Liabilities:          
Contingent liabilities 0   0   0
Level 3          
Assets:          
Derivative asset 8,288   8,288   4,989
Total assets 21,988   21,988   4,989
Liabilities:          
Derivative liabilities 0   0   0
Total liabilities 35,559   35,559   395
Level 3 | RemainCo          
Assets:          
Equity Method Investments, Fair Value Disclosure 13,700   13,700    
Level 3 | Common Stock          
Assets:          
Pelthos Common Shares 0   0   0
Level 3 | Short-Term Investments          
Assets:          
Investments, fair value 0   0   0
Level 3 | Preferred Stock          
Assets:          
Investments, fair value 0   0   0
Level 3 | Contingent liabilities          
Liabilities:          
Contingent liabilities 35,559   35,559   395
Level 3 | Contingent liabilities | CyDex          
Liabilities:          
Contingent liabilities 422   422   395
Level 3 | Contingent liabilities | Metabasis          
Liabilities:          
Contingent liabilities 0   0   0
Level 3 | Contingent liabilities | HilleVax          
Liabilities:          
Contingent liabilities 14,600   14,600   0
Level 3 | Contingent liabilities | LAVA          
Liabilities:          
Contingent liabilities 6,738   6,738   0
Level 3 | Contingent liabilities | BioInvent          
Liabilities:          
Contingent liabilities 3,300   3,300   0
Level 3 | Contingent liabilities | Pulmokine          
Liabilities:          
Contingent liabilities 4,700   4,700   0
Level 3 | Contingent liabilities | Kinnate          
Liabilities:          
Contingent liabilities 3,700   3,700   0
Level 3 | Contingent liabilities | Kinnate CVR - Exarafenib          
Liabilities:          
Contingent liabilities 2,000   2,000   0
Level 3 | Contingent liabilities | Other          
Liabilities:          
Contingent liabilities $ 99   $ 99   $ 0